Booster Vaccine Effectiveness Against Infection (3 doses vs. 2 doses) Data Table
Data as of 05/04/2022
Platform	Outcome	Age Group	Product	Schedule	Variant	Start Date	End Date	Mid-point of study period	Vaccine Effectiveness (%)	Vaccine Effectiveness 95% Lower Limit	Vaccine Effectiveness 95% Upper Limit	Figure
ICATT	Symptomatic infection	.	mRNA	3 vs. 2	Delta	12/01/21	12/31/21	12/15/21	84	83	86	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	mRNA	3 vs. 2	Omicron	12/01/21	12/31/21	12/15/21	66	64	68	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	All vaccines	3 vs. 2	Omicron	01/01/22	01/31/22	01/15/22	61.93	60.90	62.92	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	All vaccines	3 vs. 2	Omicron	02/01/22	02/28/22	02/14/22	56.19	55.06	57.30	VE (3 vs. 2 Doses) Against Infection
ICATT	Symptomatic infection	.	All vaccines	3 vs. 2	Omicron	03/01/22	03/31/22	03/15/22	33.34	29.99	36.52	VE (3 vs. 2 Doses) Against Infection

Dates are approximate

Download Data [6 KB, XLSX]

Content provided and maintained by the US Centers for Disease Control and Prevention (CDC). Please see our system usage guidelines and disclaimer.